5 Best Mid Cap Stocks To Buy Right Now

Last Thursday, outdoor sporting goods retailer Sportsman's Warehouse Holdings Inc (NASDAQ: SPWH) had an IPO that was priced�below expectations, meaning its worth taking a closer look at the stock along with the performance of peers like mid cap Cabelas Inc (NYSE: CAB) and Dicks Sporting Goods Inc (NYSE: DKS) and small cap Big 5 Sporting Goods Corporation (NASDAQ: BGFV).

What is Sportsman's Warehouse Holdings?

Founded in 1986 as a single retail store in Midvale, Utah, small cap Sportsman's Warehouse Holdings�says it has the largest outdoor specialty store base in the Western United States and Alaska (47�stores across 18 states)�that�� focused on ��eeting the everyday needs of the seasoned outdoor veteran, the first-time participant and every enthusiast in between.��The company�adds that its mission is to�provide a one-stop shopping experience that equips customers with the right hunting, shooting, fishing and camping gear to maximize their enjoyment of the outdoors.�

Hot Solar Companies To Buy Right Now: Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.

The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.

MM-398

MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.

The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.

MM-121

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.

MM-111

MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.

MM-302

MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.

MM-151

MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.

Advisors' Opinion:

• [By John Udovich]

  One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�

• [By Roberto Pedone]

   

  Another stock that insiders are jumping into here is Merrimack Pharmaceuticals (MACK), which is engaged in discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the U.S. Insiders are buying this stock into major strength, since shares have ripped higher by 38% so far in 2014.

   

   

  Merrimack Pharmaceuticals has a market cap of $765 million and an enterprise value of $713 million. This stock trades at a premium valuation, with a price-to-sales of 16.04. Its estimated growth rate for this year is 12.1, and for next year it's pegged at 17.2%. This is just barely a cash-rich company, since the total cash position on its balance sheet is $124.18 million and its total debt is $113.81 million.

   

  A director just bought 36,000 shares, or about $246,000 worth of stock, at $6.84 per share. Another director also just bought 32,390 shares, or about $221,000 worth of stock, at $6.84 per share.

   

  From a technical perspective, MACK is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock recently sold off from around $8 a share to right around its 50-day moving average of $6.69 a share. Following that move, shares of MACK have started to rebound and re-fill a previous gap-down-day zone that started near $8. That spike higher into the gap is starting to push shares of MACK within range of triggering a big breakout trade.

   

  If you're in the bull camp on MACK, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.69 and then once it breaks out above some near-term overhead resistance levels at $7.97 to its 52-week high of $8.25 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.24 million shares. If that brea

• [By Roberto Pedone]

  One under-$10 biopharmaceuticals player that's just starting to trigger a breakout trade is Merrimack Pharmaceuticals (MACK), which focuses on discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. This stock has been hit hard by the bears so far in 2013, with shares off by 38%.

  If you take a look at the chart for Merrimack Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last two months, with shares plunging from its high of 7.09 to its recent low of $3.26 a share. During that move, shares of MACK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of MACK have just formed a double bottom chart pattern at $3.26 to $3.32 a share and it's now starting to break out above some near-term overhead resistance at $3.64 a share. This move could be signaling a trend change for MACK as the stock starts to move higher off oversold conditions.

  Traders should now look for long-biased trades in MACK if it manages to break out above some near-term overhead resistance at $3.64 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout triggers soon, then MACK will set up to re-test or possibly take out its next major overhead resistance level at its 50-day moving average of $4.75 a share. Any high-volume move above that level and above more resistance at $5.06 will then give MACK a chance to tag its 200-day moving average at $5.71 a share.

  Traders can look to buy MACK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.32 or at $3.26 a share. One can also buy MACK off strength once it clears $3.64 a share with volume and then simply use a stop tha

• [By Keith Speights]

  Not so merry
  Merrimack Pharmaceuticals (NASDAQ: MACK  ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%.

5 Best Mid Cap Stocks To Buy Right Now: Guggenheim Invest S&P MidCap 400 Pure Value ETF (RFV)

Guggenheim S&P MidCap 400 Pure Value ETF (the Fund) seeks to replicate as closely as possible the performance of the S&P MidCap 400/Citigroup Pure Value Index (the Index). The Index is narrow in focus, containing only those S&P MidCap 400 companies with strong value characteristics as selected by Standard & Poor��.

The Fund uses a passive management strategy to track the performance of the Index. The Fund invests in substantially all of the securities in the Index in approximately the same proportions as in the Index. The Fund's investment advisor is Rydex Investments.

Advisors' Opinion:

• [By Holly LaFon]

  Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.

5 Best Mid Cap Stocks To Buy Right Now: Homex Development Corp (HOMEX*)

Desarrolladora Homex SAB de CV is a Mexico-based homebuilding company. Together with its subsidiaries, the Company is mainly engaged in the promotion, design, development, construction and sale of affordable entry level and middle income residential housing. The Company has four divisions: the Mexico Division; the International Division; the Infrastructure Division, and the Tourism Division. To carry out its activities, the Company engages in land acquisition, obtaining permits and licenses, designing, constructing, marketing and selling homes, obtaining individual financing for its customers and developing communities to satisfy housing needs in Mexico. The Company participates in housing supply offers from the main housing funds in Mexico. Advisors' Opinion:

• [By Julia Leite]

  Industrias CH gained 7.9 percent to 85.55 pesos today. Homex (HOMEX*) climbed 5.4 percent to 8.16 pesos, extending this week�� gains to 16 percent. Urbi gained 7.2 percent to 2.37 pesos today, advancing 16 percent in the past five days. Corp. Geo gained 1.5 percent today to 5.55 pesos, climbing 14 percent for the week.

5 Best Mid Cap Stocks To Buy Right Now: Nintendo Co Ltd (NTDOY.PK)

Nintendo Co., Ltd. is a Japan-based company mainly engaged in the leisure machine business. The Company operates in two business segments. The Leisure Machine segment is engaged in the development, manufacturing and sale of portable and console game machines as well as game software. The Others segment is engaged in the manufacture and sale of poker cards and karuta (Japanese-style playing cards), the sale of Pokemon (a Japanese animation character) goods, the management of intellectual property rights and the provision of electronic registration services of home use console machines, among others.

Advisors' Opinion:

• [By Sneha Shah]

  6) Xbox 720 - Microsoft will announce the new version of its blockbuster Xbox game console next month. Its main competitors, Sony (SNE) and Nintendo (NTDOY.PK), have already announced their new game consoles. Xbox has been a tremendous success for Microsoft and has allowed it to gain millions of subscribers for its Xbox LIVE service.